Navigation Links
BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference

determine the pharmacokinetics of BL-1020, and to assess its ability to block activity of the neurotransmitter dopamine, implicated in schizophrenia.

48 volunteers participated in the Phase I trial. They were randomized and enrolled into 6 dose cohorts at a ratio of 6:2 (BL-1020: placebo). In each cohort, patients received a single dose or matching placebo (4, 8, 16, 24, 32 or 40 mg). The results demonstrate that BL-1020 was well tolerated following administration of a single dose up to 40 mg, with no adverse drug related effects on ECG parameters, clinical lab data and neurological assessments.

About BL-1020

BL-1020 is an orally available GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. Data from preclinical and phase I studies demonstrated that the compound may retain the efficacy of currently available typical and atypical antipsychotic drugs while achieving a much higher safety profile as evidenced by a lack of metabolic or extrapyramidal side effects.

BL-1020 is designed to simultaneously target the dopamine hyperactivity and GABA hypoactivity of schizophrenia. Exogenously administered GABA is ineffective as a therapeutic agent due to its inability to cross the blood brain barrier. Pharmacokinetic studies demonstrate that BL-1020 provides effective transport of GABA into the brain, overcoming this challenge. Receptor binding studies indicate that BL-1020 has a high affinity to dopamine and specific GABA-A agonist activity. This unique clinical profile may explain the reduction in side effects observed in animals and may contribute to improving cognitive function in schizophrenia.

BL-1020 is being developed by BioLineRx, Ltd. under a worldwide exclusive license from Ramot at Tel Aviv University Ltd. and Bar-Ilan Research and Development Company Ltd., the technology transfer arms of Tel Aviv University and Bar-Ilan University respectively. BL-1020 was discovered by Professor Abraham Nudelman fro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:10/8/2008)...mab Program to be Discontinued and Headcount to be... its Portfolio Review; Zanolimumab Program to be ...r of Employees, COP...b A/S (OMX: GEN),announced today that it is discon... In addition, as a result of a portfolio review an...
(Date:10/8/2008)... program to evaluate TAXUS(R) Element(TM) Platinum...NATICK, Mass., Oct. 8 /- Bo...nounced that it has completed enrollment in,the PE...ird-generation,TAXUS(R) Element(TM) paclitaxel-elu...has enrolled nearly 1,500 patients at 100 U.S. and...
(Date:10/8/2008)..., Oct. 8 /- Vical Incorporated (Nasda...ata and new nonclinical data,demonstrating that th...pplicable in DNA- and protein-based infectious dis...lain P. Rolland, Pharm.D., Ph.D., Vical,s,Senior V... the data today,Wednesday, October 8, at the Worl...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Ultrasonic frogs can tune their ears to different frequencies 4146 1Ultrasonic frogs can tune their ears to different frequencies 4146 2Ultrasonic frogs can tune their ears to different frequencies 4146 3Insmed CEO to Present at Congressional Briefing on Follow On Biologics 2682 1Insmed CEO to Present at Congressional Briefing on Follow On Biologics 2682 2Insmed CEO to Present at Congressional Briefing on Follow On Biologics 2682 3Cynosure Receives CE Mark for Smartlipo MPX 28TM 29 Workstation 2678 1Cynosure Receives CE Mark for Smartlipo MPX 28TM 29 Workstation 2678 2Cynosure Receives CE Mark for Smartlipo MPX 28TM 29 Workstation 2678 3Minimally Invasive Treatment Improves Male Fertility 24257 1Minimally Invasive Treatment Improves Male Fertility 24257 2Minimally Invasive Treatment Improves Male Fertility 24257 3
...s, Ace393, the World,s First Commercial Vaccine,fo...ccessfully,Completes Phase I Clinical Trials , ,Tr...genicity , ODENSE, Denmark, March 28, 2007 -ACE Bi...pleased to announce the successful,completion of P...93, the world,s first commercial vaccine for Trave...
...ions Reached in Key Lung Compartments, REINACH and...rstCall/ -- Arpida Ltd. today announced promising,...se radiolabelled,Human Microdose studies included ...ndbreaking study is the first ever using Microdosi... lung compartments.,The results showed that AR-709...
Other Medicine Technology:Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5
(Date:10/10/2008)...1 in 6 likely to develop some form of disease by 2...FRIDAY, Oct. 10 (HealthDay News) -- Liver transpla... the general population, say researchers in Finlan...ssue of Liver Transplantation , researchers inves...er transplant recipients from Helsinki University ...
(Date:10/10/2008)... Eli Lilly and Company committed to helping peop...RNewswire-FirstCall/ -- In these troubling,economi...care a priority,and may feel that they don,t have ...tion. According to a survey by the National Associ...n August 2008:(1), -- Twenty-two percent of Ameri...
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... Topics range from bullyi... Boston (Vocus) October 10, 2008 -- S... Medical Center will be presenting at the 2008 Am...nd Exhibition, which runs from October 11 - 14 in ..., Pediatrician Dana Best, MD, MPH, will present ...
Breaking Medicine News(10 mins):Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference 2
...tal management to offer a pay of nearly $500,000 t...ponse to the above proposal, the Queensland Opposi...onscionable. The popular Aspen Medical Group had ...or for the emergency medicine department, with an ...
...ls in sub-Saharan Africa have joined forces to cre... allow vets// to study for postgraduate degrees wh...Veterinary E-Learning Consortium, launched in earl...vets unable to attend full-time degrees, reported ...
...run all educational and charitable institutions op...istian mission whose head was // detained in conne... and maintains schools, hospitals and orphanages i...ent earlier this month had cancelled the registrat...
...opment Minister today in New Delhi Announced that ...e status under the governments // Total Sanitation...roblem that is not faced only in rural India but a... public bathrooms, a clean sanitation environment,...
Other Medicine News:Health News:Rajasthan Plans To Run Christian Institutions 2Health News:India On The Road To Become 'Open Defecation Free' 2
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: